Central serous chorioretinopathy in primary hyperaldosteronism

被引:28
作者
van Dijk, Elon H. C. [1 ]
Nijhoff, Michiel F. [2 ,3 ]
de Jong, Eiko K. [4 ]
Meijer, Onno C. [3 ,5 ]
de Vries, Aiko P. J. [2 ]
Boon, Camiel J. F. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Ophthalmol, Dept J3 S, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Med, Div Nephrol & Transplantat, Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Med, Div Endocrinol & Metab, Leiden, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands
[5] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, Leiden, Netherlands
关键词
Central serous chorioretinopathy; Eplerenone; Hyperaldosteronism; Mineralocorticoid antagonist; Cross-sectional study; Spironolactone; OPTICAL COHERENCE TOMOGRAPHY; MINERALOCORTICOID RECEPTOR; PRIMARY ALDOSTERONISM; CHOROIDAL THICKNESS; RISK-FACTORS; DISEASE; ANTAGONISTS; VARIANTS; AGE;
D O I
10.1007/s00417-016-3417-8
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To describe ophthalmological characteristics of 13 patients with primary hyperaldosteronism (PA). Methods Cross-sectional study. All patients underwent extensive ophthalmological examination. Results Thirteen PA patients (9 male, 4 female) were diagnosed with arterial hypertension for 11.0 +/- 11.2 years. Ophthalmological imaging revealed macular serous subretinal fluid (SRF) on optical coherence tomography in 2 patients (15 %). In one of these patients, bilateral chronic central serous chorioretinopathy (CSC) with polypoidal choroidal neovasculopathy was diagnosed, which was effectively treated with full-dose photodynamic therapy. In the other patient with SRF and bilateral diffuse hyperfluorescent areas on fluorescein angiography, the SRF had decreased spontaneously after 6 weeks of follow-up. In 5 of the remaining patients (38 %), retinal pigment epithelium alterations resembling findings characteristic for CSC were seen on multimodal imaging. The mean subfoveal choroidal thickness was 290.2 +/- 65.0 mu m. Conclusions Retinal abnormalities resembling (subclinical) CSC are common in patients with PA. These findings indicate that mineralocorticoid-mediated pathways are involved in the pathogenesis of CSC. In CSC patients with hypertension of unknown origin, a diagnosis of PA should be considered.
引用
收藏
页码:2033 / 2042
页数:10
相关论文
共 50 条
  • [41] The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy
    Karagiannis, Dimitrios
    Parikakis, Efstratios
    Kontomichos, Loukas
    Batsos, Georgios
    Chatziralli, Irini
    [J]. SEMINARS IN OPHTHALMOLOGY, 2019, 34 (06) : 436 - 441
  • [42] EVALUATION OF RETINAL VESSEL DIAMETERS IN EYES WITH ACTIVE CENTRAL SEROUS CHORIORETINOPATHY
    Altunel, Orhan
    Arifoglu, Hasan Basri
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (04): : 861 - 866
  • [43] Bilateral Choroidal Thicknesses Analysis of Active and Resolved Central Serous Chorioretinopathy
    Ghadim, Banafsheh Kharrazi
    Milani, Amir Abdollah Eftekhari
    Qasemzade, Afsane
    Niyousha, Mohamad Reza
    [J]. CRESCENT JOURNAL OF MEDICAL AND BIOLOGICAL SCIENCES, 2022, 11 (01): : 47 - 52
  • [44] SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY A Randomized Controlled Crossover Study
    Bousquet, Elodie
    Beydoun, Talal
    Rothschild, Pierre-Raphael
    Bergin, Ciara
    Zhao, Min
    Batista, Rui
    Brandely, Marie-Laure
    Couraud, Benedicte
    Farman, Nicolette
    Gaudric, Alain
    Chast, Francois
    Behar-Cohen, Francine
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (12): : 2505 - 2515
  • [45] Central serous chorioretinopathy
    Pauleikhoff, Laurenz
    Agostini, Hansjurgen
    Lange, Clemens
    [J]. OPHTHALMOLOGE, 2021, 118 (09): : 967 - 980
  • [46] SCLERAL THICKNESS IN THE FELLOW EYES OF PATIENTS WITH UNILATERAL CENTRAL SEROUS CHORIORETINOPATHY
    Aichi, Takaaki
    Terao, Nobuhiro
    Imanaga, Naoya
    Sawaguchi, Shota
    Wakugawa, Sorako
    Miyara, Yasunori
    Oshiro, Ayano
    Yamauchi, Yukihide
    Koizumi, Hideki
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2023, 43 (09): : 1573 - 1578
  • [47] Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments
    Iacono, Pierluigi
    Toto, Lisa
    Costanzo, Eliana
    Varano, Monica
    Parravano, Maria Cristina
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (41) : 4864 - 4873
  • [48] Central serous chorioretinopathy with and without steroids: A multicenter survey
    Araki, Takashi
    Ishikawa, Hiroto
    Iwahashi, Chiharu
    Niki, Masanori
    Mitamura, Yoshinori
    Sugimoto, Masahiko
    Kondo, Mineo
    Kinoshita, Takamasa
    Nishi, Tomo
    Ueda, Tetsuo
    Kato, Aki
    Yasukawa, Tsutomu
    Takamura, Yoshihiro
    Gomi, Fumi
    [J]. PLOS ONE, 2019, 14 (02):
  • [49] Differential diagnoses of central serous chorioretinopathy. Is that really a central serous chorioretinopathy?
    Lange, C.
    Aschauer, J.
    Hufnagel, H.
    Pauleikhoff, L.
    [J]. OPHTHALMOLOGIE, 2025, 122 (03): : 178 - 185
  • [50] RISK OF RHEGMATOGENOUS RETINAL DETACHMENT WITH CENTRAL SEROUS CHORIORETINOPATHY
    Chang, Yuh-Shin
    Chang, Chun
    Weng, Shih-Feng
    Wang, Jhi-Joung
    Jan, Ren-Long
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (08): : 1446 - 1453